Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks (clinicaltrials.gov) - Oct 3, 2026 - P3 | N=382 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|